Precipio (NASDAQ:PRPO) Stock Passes Above Two Hundred Day Moving Average – Time to Sell?

Precipio, Inc. (NASDAQ:PRPO) shares passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $24.78 and traded as high as $29.08. Precipio shares last traded at $28.70, with a volume of 50,416 shares trading hands.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Wall Street Zen raised shares of Precipio from a “hold” rating to a “buy” rating in a research report on Saturday, April 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Precipio in a research report on Tuesday, April 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Precipio Price Performance

The company has a market cap of $51.09 million, a price-to-earnings ratio of -114.80 and a beta of 1.38. The company has a fifty day moving average price of $27.79 and a two-hundred day moving average price of $24.78. The company has a current ratio of 1.61, a quick ratio of 1.36 and a debt-to-equity ratio of 0.05.

Precipio (NASDAQ:PRPO) last issued its earnings results on Monday, March 30th. The biotechnology company reported $0.34 EPS for the quarter. The business had revenue of $6.70 million during the quarter. Precipio had a negative return on equity of 2.78% and a negative net margin of 1.51%.

Institutional Trading of Precipio

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. AMH Equity Ltd raised its position in Precipio by 370.1% in the third quarter. AMH Equity Ltd now owns 131,100 shares of the biotechnology company’s stock worth $2,332,000 after purchasing an additional 103,210 shares in the last quarter. Evernest Financial Advisors LLC acquired a new stake in Precipio during the third quarter valued at approximately $374,000. Topline Capital Management LLC bought a new stake in shares of Precipio in the 3rd quarter valued at approximately $1,158,000. Susquehanna International Group LLP bought a new stake in shares of Precipio in the 3rd quarter valued at approximately $194,000. Finally, Geode Capital Management LLC raised its holdings in shares of Precipio by 5.1% in the 4th quarter. Geode Capital Management LLC now owns 16,388 shares of the biotechnology company’s stock worth $377,000 after buying an additional 789 shares in the last quarter. Institutional investors own 10.45% of the company’s stock.

About Precipio

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.